{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T04:16:52Z","timestamp":1788322612592,"version":"build-2803163510"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-72745-6","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T01:35:52Z","timestamp":1778290552000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Anti-PD-1 plus nab-paclitaxel and bevacizumab for second-line treatment of cancer of unknown primary (Fudan CUP-002): a phase II trial"],"prefix":"10.1038","volume":"17","author":[{"given":"Xiaowei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1775-6608","authenticated-orcid":false,"given":"Midie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qifeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangping","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghua","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4760-9637","authenticated-orcid":false,"given":"Xichun","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0389-2350","authenticated-orcid":false,"given":"Zhiguo","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,9]]},"reference":[{"key":"72745_CR1","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.annonc.2022.11.013","volume":"34","author":"A Kramer","year":"2023","unstructured":"Kramer, A. et al. Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 34, 228\u2013246 (2023).","journal-title":"Ann. Oncol."},{"key":"72745_CR2","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1093\/annonc\/mdr536","volume":"23","author":"K Hemminki","year":"2012","unstructured":"Hemminki, K., Bevier, M., Hemminki, A. & Sundquist, J. Survival in cancer of unknown primary site: population-based analysis by site and histology. Ann. Oncol. 23, 1854\u20131863 (2012).","journal-title":"Ann. Oncol."},{"key":"72745_CR3","doi-asserted-by":"publisher","first-page":"m4050","DOI":"10.1136\/bmj.m4050","volume":"371","author":"MS Lee","year":"2020","unstructured":"Lee, M. S. & Sanoff, H. K. Cancer of unknown primary. BMJ 371, m4050 (2020).","journal-title":"BMJ"},{"key":"72745_CR4","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1016\/S0140-6736(11)61178-1","volume":"379","author":"N Pavlidis","year":"2012","unstructured":"Pavlidis, N. & Pentheroudakis, G. Cancer of unknown primary site. Lancet 379, 1428\u20131435 (2012).","journal-title":"Lancet"},{"key":"72745_CR5","doi-asserted-by":"publisher","first-page":"3101","DOI":"10.1200\/JCO.2000.18.17.3101","volume":"18","author":"E Briasoulis","year":"2000","unstructured":"Briasoulis, E. et al. Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study. J. Clin. Oncol. 18, 3101\u20133107 (2000).","journal-title":"J. Clin. Oncol."},{"key":"72745_CR6","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/S1470-2045(24)00313-9","volume":"25","author":"X Liu","year":"2024","unstructured":"Liu, X. et al. Site-specific therapy guided by a 90-gene expression assay versus empirical chemotherapy in patients with cancer of unknown primary (Fudan CUP-001): a randomised controlled trial. Lancet Oncol. 25, 1092\u20131102 (2024).","journal-title":"Lancet Oncol."},{"key":"72745_CR7","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1200\/JCO.18.00771","volume":"37","author":"H Hayashi","year":"2019","unstructured":"Hayashi, H. et al. Randomized phase II Trial comparing site-specific treatment based on gene expression profiling with carboplatin and paclitaxel for patients with cancer of unknown primary site. J. Clin. Oncol. 37, 570\u2013579 (2019).","journal-title":"J. Clin. Oncol."},{"key":"72745_CR8","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1001\/jamaoncol.2020.4643","volume":"6","author":"H Hayashi","year":"2020","unstructured":"Hayashi, H. et al. Site-specific and targeted therapy based on molecular profiling by next-generation sequencing for cancer of unknown primary site: a nonrandomized phase 2 clinical trial. JAMA Oncol. 6, 1931\u20131938 (2020).","journal-title":"JAMA Oncol."},{"key":"72745_CR9","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/nrclinonc.2011.158","volume":"8","author":"C Massard","year":"2011","unstructured":"Massard, C., Loriot, Y. & Fizazi, K. Carcinomas of an unknown primary origin-diagnosis and treatment. Nat. Rev. Clin. Oncol. 8, 701\u2013710 (2011).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"72745_CR10","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1081\/CNV-100103127","volume":"19","author":"JD Hainsworth","year":"2001","unstructured":"Hainsworth, J. D. et al. Gemcitabine in the second-line therapy of patients with carcinoma of unknown primary site: a phase II trial of the Minnie Pearl Cancer Research Network. Cancer Invest. 19, 335\u2013339 (2001).","journal-title":"Cancer Invest."},{"key":"72745_CR11","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1002\/cncr.21416","volume":"104","author":"JD Hainsworth","year":"2005","unstructured":"Hainsworth, J. D. et al. Combination chemotherapy with gemcitabine and irinotecan in patients with previously treated carcinoma of an unknown primary site: a Minnie Pearl Cancer Research Network Phase II trial. Cancer 104, 1992\u20131997 (2005).","journal-title":"Cancer"},{"key":"72745_CR12","doi-asserted-by":"publisher","first-page":"431","DOI":"10.3109\/02841861003649240","volume":"49","author":"AK Moller","year":"2010","unstructured":"Moller, A. K., Pedersen, K. D., Abildgaard, J., Petersen, B. L. & Daugaard, G. Capecitabine and oxaliplatin as second-line treatment in patients with carcinoma of unknown primary site. Acta Oncol. 49, 431\u2013435 (2010).","journal-title":"Acta Oncol."},{"key":"72745_CR13","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1002\/cncr.25029","volume":"116","author":"JD Hainsworth","year":"2010","unstructured":"Hainsworth, J. D. et al. Oxaliplatin and capecitabine in the treatment of patients with recurrent or refractory carcinoma of unknown primary site: a phase 2 trial of the Sarah Cannon Oncology Research Consortium. Cancer 116, 2448\u20132454 (2010).","journal-title":"Cancer"},{"key":"72745_CR14","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1200\/JCO.2006.09.3047","volume":"25","author":"JD Hainsworth","year":"2007","unstructured":"Hainsworth, J. D. et al. Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie Pearl Cancer Research Network. J. Clin. Oncol. 25, 1747\u20131752 (2007).","journal-title":"J. Clin. Oncol."},{"key":"72745_CR15","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41571-020-0359-1","volume":"17","author":"E Rassy","year":"2020","unstructured":"Rassy, E. & Pavlidis, N. Progress in refining the clinical management of cancer of unknown primary in the molecular era. Nat. Rev. Clin. Oncol. 17, 541\u2013554 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"72745_CR16","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/s40425-019-0720-z","volume":"7","author":"K Haratani","year":"2019","unstructured":"Haratani, K. et al. Clinical and immune profiling for cancer of unknown primary site. J. Immunother. Cancer 7, 251 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"72745_CR17","doi-asserted-by":"publisher","first-page":"e394","DOI":"10.1002\/onco.13597","volume":"26","author":"JS Ross","year":"2021","unstructured":"Ross, J. S. et al. Comprehensive genomic profiling of carcinoma of unknown primary origin: retrospective molecular classification considering the CUPISCO study design. Oncologist 26, e394\u2013e402 (2021).","journal-title":"Oncologist"},{"key":"72745_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12437-w","volume":"24","author":"HM Kim","year":"2024","unstructured":"Kim, H. M. & Koo, J. S. Programmed death-ligand 1 expression in carcinoma of unknown primary. BMC Cancer 24, 689 (2024).","journal-title":"BMC Cancer"},{"key":"72745_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114268","volume":"210","author":"T Abu Sabbah","year":"2024","unstructured":"Abu Sabbah, T. et al. PD-L1 expression associates with favorable survival of patients with cancer of unknown primary (CUP) not treated with checkpoint inhibitors. Eur. J. Cancer 210, 114268 (2024).","journal-title":"Eur. J. Cancer"},{"key":"72745_CR20","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.ejca.2018.02.021","volume":"94","author":"Z Gatalica","year":"2018","unstructured":"Gatalica, Z., Xiu, J., Swensen, J. & Vranic, S. Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy. Eur. J. Cancer 94, 179\u2013186 (2018).","journal-title":"Eur. J. Cancer"},{"key":"72745_CR21","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.annonc.2021.11.009","volume":"33","author":"J Tanizaki","year":"2022","unstructured":"Tanizaki, J. et al. Open-label phase II study of the efficacy of nivolumab for cancer of unknown primary. Ann. Oncol. 33, 216\u2013226 (2022).","journal-title":"Ann. Oncol."},{"key":"72745_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42400-5","volume":"14","author":"M Pouyiourou","year":"2023","unstructured":"Pouyiourou, M. et al. Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial. Nat. Commun. 14, 6761 (2023).","journal-title":"Nat. Commun."},{"key":"72745_CR23","doi-asserted-by":"publisher","first-page":"e004822","DOI":"10.1136\/jitc-2022-004822","volume":"10","author":"KP Raghav","year":"2022","unstructured":"Raghav, K. P. et al. Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial. J. Immunother. Cancer 10, e004822 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"72745_CR24","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/s41568-024-00736-0","volume":"24","author":"S Guelfi","year":"2024","unstructured":"Guelfi, S., Hodivala-Dilke, K. & Bergers, G. Targeting the tumour vasculature: from vessel destruction to promotion. Nat. Rev. Cancer 24, 655\u2013675 (2024).","journal-title":"Nat. Rev. Cancer"},{"key":"72745_CR25","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1038\/s41571-024-00886-y","volume":"21","author":"HY Kuo","year":"2024","unstructured":"Kuo, H. Y., Khan, K. A. & Kerbel, R. S. Antiangiogenic-immune-checkpoint inhibitor combinations: lessons from phase III clinical trials. Nat. Rev. Clin. Oncol. 21, 468\u2013482 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"72745_CR26","doi-asserted-by":"publisher","first-page":"4768","DOI":"10.1200\/JCO.23.00529","volume":"41","author":"JE Kurtz","year":"2023","unstructured":"Kurtz, J. E. et al. Atezolizumab combined with bevacizumab and platinum-based therapy for platinum-sensitive ovarian cancer: placebo-controlled randomized phase III ATALANTE\/ENGOT-ov29 trial. J. Clin. Oncol. 41, 4768\u20134778 (2023).","journal-title":"J. Clin. Oncol."},{"key":"72745_CR27","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(23)02405-4","volume":"403","author":"A Oaknin","year":"2024","unstructured":"Oaknin, A. et al. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomized, open-label, phase 3 trial. Lancet 403, 31\u201343 (2024).","journal-title":"Lancet"},{"key":"72745_CR28","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/j.jtho.2021.07.009","volume":"16","author":"MA Socinski","year":"2021","unstructured":"Socinski, M. A. et al. IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous NSCLC. J. Thorac. Oncol. 16, 1909\u20131924 (2021).","journal-title":"J. Thorac. Oncol."},{"key":"72745_CR29","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.immuni.2022.12.001","volume":"56","author":"A Chow","year":"2023","unstructured":"Chow, A. et al. The ectonucleotidase CD39 identifies tumor-reactive CD8(+) T cells predictive of immune checkpoint blockade efficacy in human lung cancer. Immunity 56, 93\u2013106 e106 (2023).","journal-title":"Immunity"},{"key":"72745_CR30","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/j.cell.2025.12.026","volume":"189","author":"E Salazar-Cavazos","year":"2026","unstructured":"Salazar-Cavazos, E. et al. Stochasticity in cancer immunotherapy stems from rare but functionally critical Spark T cells. Cell 189, 1074\u20131085 e1023 (2026).","journal-title":"Cell"},{"key":"72745_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.102882","volume":"147","author":"E Rassy","year":"2020","unstructured":"Rassy, E. et al. New rising entities in cancer of unknown primary: Is there a real therapeutic benefit?. Crit. Rev. Oncol. Hematol. 147, 102882 (2020).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"72745_CR32","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn, R. S. et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med 382, 1894\u20131905 (2020).","journal-title":"N. Engl. J. Med"},{"key":"72745_CR33","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ccell.2022.11.014","volume":"41","author":"OS Blomberg","year":"2023","unstructured":"Blomberg, O. S. et al. IL-5-producing CD4(+) T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer. Cancer Cell 41, 106\u2013123 e110 (2023).","journal-title":"Cancer Cell"},{"key":"72745_CR34","doi-asserted-by":"publisher","first-page":"5453","DOI":"10.1158\/1078-0432.CCR-15-0676","volume":"21","author":"C Gebhardt","year":"2015","unstructured":"Gebhardt, C. et al. Myeloid cells and related chronic inflammatory factors as novel predictive markers in melanoma treatment with ipilimumab. Clin. Cancer Res 21, 5453\u20135459 (2015).","journal-title":"Clin. Cancer Res"},{"key":"72745_CR35","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1038\/s41590-022-01291-2","volume":"23","author":"S Grisaru-Tal","year":"2022","unstructured":"Grisaru-Tal, S., Rothenberg, M. E. & Munitz, A. Eosinophil-lymphocyte interactions in the tumor microenvironment and cancer immunotherapy. Nat. Immunol. 23, 1309\u20131316 (2022).","journal-title":"Nat. Immunol."},{"key":"72745_CR36","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/nrclinonc.2018.9","volume":"15","author":"KA Khan","year":"2018","unstructured":"Khan, K. A. & Kerbel, R. S. Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa. Nat. Rev. Clin. Oncol. 15, 310\u2013324 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"72745_CR37","doi-asserted-by":"publisher","first-page":"102106","DOI":"10.1016\/j.eclinm.2023.102106","volume":"62","author":"Y Zhao","year":"2023","unstructured":"Zhao, Y. et al. AK112, a novel PD-1\/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial. EClinicalMedicine 62, 102106 (2023).","journal-title":"EClinicalMedicine"},{"key":"72745_CR38","doi-asserted-by":"publisher","first-page":"e008037","DOI":"10.1136\/jitc-2023-008037","volume":"12","author":"S Frentzas","year":"2024","unstructured":"Frentzas, S. et al. Phase 1a dose escalation study of ivonescimab (AK112\/SMT112), an anti-PD-1\/VEGF-A bispecific antibody, in patients with advanced solid tumors. J. Immunother. Cancer 12, e008037 (2024).","journal-title":"J. Immunother. Cancer"},{"key":"72745_CR39","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41586-022-05628-7","volume":"615","author":"A Gurtner","year":"2023","unstructured":"Gurtner, A. et al. Active eosinophils regulate host defense and immune responses in colitis. Nature 615, 151\u2013157 (2023).","journal-title":"Nature"},{"key":"72745_CR40","doi-asserted-by":"publisher","first-page":"eabc7609","DOI":"10.1126\/sciadv.abc7609","volume":"7","author":"JN Cheng","year":"2021","unstructured":"Cheng, J. N. et al. Radiation-induced eosinophils improve cytotoxic T lymphocyte recruitment and response to immunotherapy. Sci. Adv. 7, eabc7609 (2021).","journal-title":"Sci. Adv."},{"key":"72745_CR41","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/modpathol.2016.42","volume":"29","author":"AE Prizment","year":"2016","unstructured":"Prizment, A. E. et al. Tumor eosinophil infiltration and improved survival of colorectal cancer patients: Iowa Women\u2019s Health Study. Mod. Pathol. 29, 516\u2013527 (2016).","journal-title":"Mod. Pathol."},{"key":"72745_CR42","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.jpainsymman.2009.09.019","volume":"39","author":"JL Steel","year":"2010","unstructured":"Steel, J. L. et al. Cancer-related symptom clusters, eosinophils, and survival in hepatobiliary cancer: an exploratory study. J. Pain. Symptom Manag. 39, 859\u2013871 (2010).","journal-title":"J. Pain. Symptom Manag."},{"key":"72745_CR43","doi-asserted-by":"publisher","first-page":"9718","DOI":"10.3390\/ijms15069718","volume":"15","author":"Y Zhang","year":"2014","unstructured":"Zhang, Y. et al. Clinical impact of tumor-infiltrating inflammatory cells in primary small cell esophageal carcinoma. Int J. Mol. Sci. 15, 9718\u20139734 (2014).","journal-title":"Int J. Mol. Sci."},{"key":"72745_CR44","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/s41392-024-01752-0","volume":"9","author":"J Zhou","year":"2024","unstructured":"Zhou, J. et al. Eosinophils promote CD8(+) T cell memory generation to potentiate anti-bacterial immunity. Signal Transduct. Target Ther. 9, 43 (2024).","journal-title":"Signal Transduct. Target Ther."},{"key":"72745_CR45","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/ni.3159","volume":"16","author":"R Carretero","year":"2015","unstructured":"Carretero, R. et al. Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells. Nat. Immunol. 16, 609\u2013617 (2015).","journal-title":"Nat. Immunol."},{"key":"72745_CR46","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/s41568-020-0283-9","volume":"20","author":"S Grisaru-Tal","year":"2020","unstructured":"Grisaru-Tal, S., Itan, M., Klion, A. D. & Munitz, A. A new dawn for eosinophils in the tumour microenvironment. Nat. Rev. Cancer 20, 594\u2013607 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"72745_CR47","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1038\/s41591-025-03776-7","volume":"31","author":"SY Wu","year":"2025","unstructured":"Wu, S. Y. et al. Mobilizing antigen-presenting mast cells in anti-PD-1-refractory triple-negative breast cancer: a phase 2 trial. Nat. Med 31, 2405\u20132415 (2025).","journal-title":"Nat. Med"},{"key":"72745_CR48","doi-asserted-by":"publisher","first-page":"e769","DOI":"10.1002\/onco.13744","volume":"26","author":"C Pauli","year":"2021","unstructured":"Pauli, C. et al. A challenging task: identifying patients with Cancer of Unknown Primary (CUP) according to ESMO guidelines: the CUPISCO trial experience. Oncologist 26, e769\u2013e779 (2021).","journal-title":"Oncologist"},{"key":"72745_CR49","doi-asserted-by":"publisher","first-page":"eabb5943","DOI":"10.1126\/sciadv.abb5943","volume":"7","author":"F Li","year":"2021","unstructured":"Li, F. et al. Eosinophilic inflammation promotes CCL6-dependent metastatic tumor growth. Sci. Adv. 7, eabb5943 (2021).","journal-title":"Sci. Adv."},{"key":"72745_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2022.100855","volume":"35","author":"TL Lee","year":"2023","unstructured":"Lee, T. L. et al. Tumor-associated tissue eosinophilia promotes angiogenesis and metastasis in head and neck squamous cell carcinoma. Neoplasia 35, 100855 (2023).","journal-title":"Neoplasia"},{"key":"72745_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1148798","volume":"14","author":"M Willems","year":"2023","unstructured":"Willems, M. et al. Excess of blood eosinophils prior to therapy correlates with worse prognosis in mesothelioma. Front. Immunol. 14, 1148798 (2023).","journal-title":"Front. Immunol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72745-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72745-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72745-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T07:03:47Z","timestamp":1784185427000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72745-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,9]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["72745"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-72745-6","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,9]]},"assertion":[{"value":"4 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Q.H.X. is an employee of Canhelp Genomics in Hangzhou, China. All other authors have declared no potential conflicts of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"6263"}}